Novartis CEO Says Lek Well-Positioned in Central Europe, Russia
Ljubljana, 24 March - The CEO of the Swiss pharmaceutical giant, Novartis, has said that Ljubljana-based Lek, a subsidiary of Novartis' generic group Sandoz, is well-positioned on the markets of Eastern Europe and Russia, which afford enormous growth potential.
The rest of this news item is available to subscribers.
The news item consists of 1.747 characters (without spaces) or 347 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.